Who are PLA + MTX switched to ABA+ MTX, DB's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): abatacept infusion, Placebo matching with Abatacept, IV Abatacept, Intravenous (IV) abatacept, Abatacept (W12-W48), Open-label Abatacept.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/pla-mtx-switched-to-aba-mtx-db.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

PLA + MTX switched to ABA+ MTX, DB — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

PLA + MTX switched to ABA+ MTX, DB (PLA + MTX switched to ABA+ MTX, DB) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: T-cell costimulation inhibitor. Area: Immunology.

phase 3 T-cell costimulation inhibitor CD80/CD86 (on antigen-presenting cells); CD28 (on T cells) Immunology Small molecule Live · refreshed every 30 min

Target snapshot

PLA + MTX switched to ABA+ MTX, DB (PLA + MTX switched to ABA+ MTX, DB) — Bristol-Myers Squibb. Abatacept (ABA) is a T-cell costimulation inhibitor that blocks the interaction between antigen-presenting cells and T cells, reducing inflammatory immune responses when combined with methotrexate (MTX).

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
PLA + MTX switched to ABA+ MTX, DB TARGET	PLA + MTX switched to ABA+ MTX, DB	Bristol-Myers Squibb	phase 3	T-cell costimulation inhibitor	CD80/CD86 (on antigen-presenting cells); CD28 (on T cells)
abatacept infusion	abatacept infusion	University of Minnesota	marketed	T-cell costimulation inhibitor	CD80/CD86
Placebo matching with Abatacept	Placebo matching with Abatacept	Bristol-Myers Squibb	marketed	CTLA-4 fusion protein; T-cell costimulation inhibitor	CD80, CD86
IV Abatacept	IV Abatacept	Rüdiger B. Müller	marketed	T-cell costimulation inhibitor	CD80/CD86
Intravenous (IV) abatacept	Intravenous (IV) abatacept	Bristol-Myers Squibb	phase 3	CTLA-4 fusion protein; T-cell costimulation inhibitor	CD80, CD86
Abatacept (W12-W48)	Abatacept (W12-W48)	University Hospital, Montpellier	phase 3	T-cell costimulation inhibitor	CD80/CD86
Open-label Abatacept	Open-label Abatacept	Bristol-Myers Squibb	phase 3	CTLA-4 fusion protein (T-cell costimulation inhibitor)	CD80/CD86

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (T-cell costimulation inhibitor class)

Bristol-Myers Squibb · 1 drug in this class
Rüdiger B. Müller · 1 drug in this class
University Hospital, Montpellier · 1 drug in this class
University of Minnesota · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). PLA + MTX switched to ABA+ MTX, DB — Competitive Intelligence Brief. https://druglandscape.com/ci/pla-mtx-switched-to-aba-mtx-db. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab